Stockscreener 앱 받기
4.04
9.19%
0.34
시장 영업 전:
4.09
0.05
+1.24%
Prime Medicine Inc 주식(PRME)의 최신 뉴스
Prime Medicine (NYSE:PRME) Trading 7.5% HigherWhat's Next? - MarketBeat
How Prime Medicine Inc. stock reacts to oil pricesBullish Engulfing Patterns & High Profit Trading Alerts - ulpravda.ru
Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Prime Medicine, Inc. (PRME) announces NEJM publication of PM359 data - MSN
Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize - Benzinga
Prime: Maintaining "Buy" On Solidified Catalysts For Wilson's Disease And Beyond - Seeking Alpha
Prime Medicine (NYSE:PRME) Trading Down 3.3%Here's What Happened - MarketBeat
LifeSci Capital Initiates Prime Medicine (PRME), Highlights One-and-Done Potential in Liver and Lung Diseases - Insider Monkey
Prime Medicine, Inc. (PRME) Announces NEJM Publication Of PM359 Data - Insider Monkey
10 Best Biotech Penny Stocks to Buy According to Analysts - Insider Monkey
Lifesci Capital Predicts Prime Medicine FY2025 Earnings - MarketBeat
Prime Medicine (NASDAQ:PRME) Trading Down 3.8%Here's What Happened - MarketBeat
Prime Medicine (NYSE:PRME) Stock Price Down 4.2%Should You Sell? - MarketBeat
Prime Medicine (NASDAQ:PRME) Upgraded at Lifesci Capital - MarketBeat
LifeSci Capital Initiates Coverage of Prime Medicine (PRME) with Outperform Recommendation - Nasdaq
Lifesci Capital Begins Coverage on Prime Medicine (NYSE:PRME) - MarketBeat
LifeSci Capital Initiates Prime Medicine(PRME.US) With Buy Rating, Announces Target Price $6 - 富途牛牛
Prime Medicine: Buy Rating on Prime Editing Platform Targeting High-Value Liver and Lung Genetic Diseases, Led by PM577 in Wilson’s Disease - TipRanks
Prime Medicine initiated with an Outperform at LifeSci Capital - TipRanks
LifeSci Initiates Prime Medicine at Outperform With $6 Price Target - marketscreener.com
Prime Medicine Earnings Notes - Trefis
Prime Medicine, Inc.(NasdaqGM: PRME) added to S&P Biotechnology Select Industry Index - marketscreener.com
Prime Medicine announces NEJM publication of PM359 data - MSN
Prime Medicine, Inc. (NYSE:PRME) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Quarterly Recap: How Prime Medicine Inc. stock reacts to oil pricesWatch List & Safe Entry Trade Reports - Улправда
Risks Report: Why Prime Medicine Inc. stock remains resilient2025 Market Trends & Real-Time Buy Signal Notifications - Улправда
What technical charts say about Prime Medicine Inc. stockEarnings Overview Report & AI Powered Market Entry Strategies - Улправда
Why Prime Medicine Inc. stock remains resilientTrade Exit Summary & Weekly High Return Stock Forecasts - Улправда
Can Prime Medicine Inc. stock hit record highs againJuly 2025 News Drivers & Weekly High Conviction Ideas - Улправда
Can Prime Medicine Inc. stock withstand economic slowdownTrade Signal Summary & Weekly Top Gainers Alerts - Улправда
Is Prime Medicine Inc. stock in correction or buying zone2025 Stock Rankings & Consistent Growth Equity Picks - DonanımHaber
Profit Recap: How Prime Medicine Inc. stock reacts to oil pricesRate Hike & Accurate Intraday Trading Signals - Улправда
Prime Medicine's Market Cap Up US$161m Following Year Of Insider Stock Buying - simplywall.st
Prime Medicine’s Stock Fluctuations: How Genomic Advances Steer Performance - StocksToTrade
Prime Medicine (NYSE:PRME) Shares Gap UpShould You Buy? - MarketBeat
Prime Medicine (NASDAQ:PRME) Shares Gap UpStill a Buy? - MarketBeat
Prime Medicine Announces The New England Journal of - GlobeNewswire
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease - Sahm
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Prime Medicine (NYSE:PRME) Stock Price Up 10.2%Still a Buy? - MarketBeat
Prime Medicine (NASDAQ:PRME) Trading Up 11.1%Here's What Happened - MarketBeat
Will Prime Medicine Inc. stock deliver better than expected guidance2025 Sector Review & Safe Capital Preservation Plans - Newser
Prime Medicine (PRME) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Prime Medicine (NASDAQ:PRME) Stock Price Down 7.3%Here's What Happened - MarketBeat
Prime Medicine (NYSE:PRME) Stock Price Down 7.2%Here's Why - MarketBeat
PRME: Prime editing advances with focused clinical programs and data expected in 2027 - TradingView — Track All Markets
Prime Medicine (PRME) Competitors and Alternatives 2025 - MarketBeat
Prime Medicine, Inc. (NYSE:PRME) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
28.63%
자본화:
|
볼륨(24시간):